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Abstract
Drug-drug interaction (DDI) is a major cause of morbidity and mortality and a subject of intense scien-
tific interest. Biomedical literature mining can aid DDI research by extracting evidence for large numbers
of potential interactions from published literature and clinical databases. Though DDI is investigated
in domains ranging in scale from intracellular biochemistry to human populations, literature mining
has not been used to extract specific types of experimental evidence, which are reported differently for
distinct experimental goals. We focus on pharmacokinetic evidence for DDI, essential for identifying
causal mechanisms of putative interactions and as input for further pharmacological and pharmaco-
epidemiology investigations. We used manually curated corpora of PubMed abstracts and annotated
sentences to evaluate the efficacy of literature mining on two tasks: first, identifying PubMed abstracts
containing pharmacokinetic evidence of DDIs; second, extracting sentences containing such evidence from
abstracts. We implemented a text mining pipeline and evaluated it using several linear classifiers and
a variety of feature transforms. The most important textual features in the abstract and sentence clas-
sification tasks were analyzed. We also investigated the performance benefits of using features derived
from PubMed metadata fields, various publicly available named entity recognizers, and pharmacokinetic
dictionaries. Several classifiers performed very well in distinguishing relevant and irrelevant abstracts
(reaching F1≈0.93, MCC≈0.74, iAUC≈0.99) and sentences (F1≈0.76, MCC≈0.65, iAUC≈0.83). We
found that word bigram features were important for achieving optimal classifier performance and that
features derived from Medical Subject Headings (MeSH) terms significantly improved abstract classifica-
tion. We also found that some drug-related named entity recognition tools and dictionaries led to slight
but significant improvements, especially in classification of evidence sentences. Based on our thorough
analysis of classifiers and feature transforms and the high classification performance achieved, we demon-
strate that literature mining can aid DDI discovery by supporting automatic extraction of specific types
of experimental evidence.
Introduction
Drug-drug interaction (DDI) is one of the major causes of adverse drug reaction (ADR) and a threat
to public health. Pharmaco-epidemiology studies [1] and recent National Health Statistics Report pub-
lications [2, 3] indicate that each year an estimated 195,000 hospitalizations and 74,000 emergency room
visits are the result of DDI in the United States alone [4]. DDI has been implicated in nearly 3% of
all hospital admissions [5] and 4.8% of admissions among the elderly [1] and is a common consequence
of medical error, representing 3% to 5% of all inpatient medication errors [6]. With increasing rates of
polypharmacy, which refers to the use of multiple medications or more medications than are clinically
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2indicated [7], the incidence of DDI will likely increase in the coming years.
Researchers link molecular mechanisms underlying DDI to their clinical consequences through three
types of studies: in vitro, in vivo, and clinical [8–10]. In vitro pharmacology experiments use intact
cells (e.g. hepatocytes), microsomal protein fractions, or recombinant systems to investigate molecular
interaction mechanisms within the cell (i.e. metabolic, transport- or target-based). In vivo studies
evaluate whether such interactions impact drug exposure in humans. Finally, clinical studies use a
population-based approach and large electronic medical record databases to investigate the contribution
of DDI to drug efficacy and ADR.
Automated biomedical literature mining (BLM) methods offer a promising approach for uncovering
evidence of possible DDI in published literature and clinical databases [11]. BLM is a biomedical infor-
matics methodology that holds the promise of tapping into the biomedical collective knowledge [12] by
extracting information from large-scale literature repositories and by integrating information scattered
across various domain-specific databases and ontologies [13–15]. It has been used for knowledge dis-
covery in many biomedical domains, including extraction of protein-protein interactions [16, 17], protein
structure prediction [18], identification of genomic locations associated with cancer [19], and mining drug
targets [20]. In the domain of DDI, putative interactions uncovered by BLM can serve as targets for
subsequent investigation by in vitro pharmacological methods as well as in vivo and clinical studies [11].
BLM has previously been used for DDI information extraction [21–26], as overviewed by the literature
on recent DDI challenges [27–29] and Pacific Symposium on Biocomputing sessions [30, 31]. However,
much remains to be done in automatic extraction of experimental evidence of DDI from text. Impor-
tantly, experimental evidence of DDI is reported differently for the different types of studies described
above. For instance, in vivo pharmacokinetic experiments report parameters such as the ‘area under the
concentration-time curve’, while clinical studies may instead report population-level statistics of adverse
drug reactions. It is important for BLM pipelines to be able to identify these different kinds of evidence
independently.
To address this situation, we demonstrate the use BLM for reliable extraction of pharmacokinetic
evidence for DDI from reports of in vitro and in vivo experiments. Pharmacokinetic experimental evidence
refers to measures of pharmacokinetic parameters such as the inhibition constant (Ki), the 50% inhibitory
concentration (IC50), and the area under the plasma concentration-time curve (AUCR). Such evidence
is particularly important in identifying or dismissing causal mechanisms behind DDIs and in providing
support for putative DDIs extracted from mining patient records, where biases and confounds in reporting
often give rise to non-causal correlations [32]. In order to pursue the goal of using BLM to uncover
pharmacokinetic DDI evidence, a collaboration was developed between Rocha’s lab, working on literature
mining, and Li’s lab, working on pharmacokinetics. Though this work is focused on pharmacokinetic
evidence, in subsequent studies we will approach other types of DDI evidence (e.g. clinical evidence).
Our approach is different from previous BLM approaches to DDI information extraction [21–26, 28]
because our ultimate goal is not to identify interacting drugs themselves but rather abstracts and sentences
containing a specific type of evidence of drug interaction. Existing DDI-extraction methods and corpora
— including those evaluated under the DDI Extraction challenges [27–29, 33, 34] — are not well suited
for this task because they do not attempt to extract experimental evidence of drug interactions, nor
specifically label distinct kinds of evidence. For instance, the DDI Extraction challenge ‘11 [33] used
a corpus of several hundred documents from DrugBank [35], but interacting drug pairs were annotated
without regard for the presence of experimental evidence. More recently, the DDI Extraction challenge
‘13 [34] provided a corpus annotated with pharmacokinetic and pharmacodynamic interactions [29], but
the goal of the text mining task was the extraction and classification of interacting drug pairs, not the
extraction of the experimental evidence of interactions. Other related work has used DrugBank data for
large-scale extraction of drug-gene and drug-drug relationships [22, 36], and for predicting DDI using a
drug-drug network based on phenotypic, therapeutic, chemical, and genomic feature similarity [37], but
neither study aimed to identify or extract specific kinds experimental evidence of DDI.
3We have previously shown that BLM can be used for automatic extraction of numerical pharmacoki-
netics (PK) parameters from the literature [38]. However, that work was not oriented specifically toward
the extraction of evidence of DDI. Recently, we reported high performance in a preliminary work on
automatically classifying PubMed abstracts that contain pharmacokinetic evidence of DDI [39] (details
below). Because identifying relevant abstracts is only a first step in the process of extracting pharma-
cokinetic evidence of DDI, in this work we consider both the problem of identifying abstracts containing
pharmacokinetic evidence of DDI and that of extracting from abstracts sentences that contain this spe-
cific kind of evidence. In addition to evidence sentence extraction, we also provide a new assessment of
abstract classification using an updated version of a separately published corpus [26], leading to substan-
tially better classification performance than reported in our preliminary study [39]. The updated corpus
is described below and is publicly available. Finally, we provide a new comparison of classifiers, a new
evaluation methodology using permutation-based significance tests and Principal Component Analysis
(PCA) [40] of feature weights, and a detailed study of the benefits of including features derived from
PubMed metadata, named entity recognition tools and specialized dictionaries.
We created abstract and sentence corpora using annotation criteria for identifying pharmacokinetic
evidence of DDI. We consider positive (indicating the presence of interactions) and negative (indicating
the absence) DDI evidence as relevant (see “Materials and Methods” section), since both provide important
information about possible DDI. Because the criteria considered here are different from those used in
previously available DDI corpora, our results are not directly comparable to other BLM approaches to
DDI. Therefore, we pursued a thorough evaluation of the performance of different types of classifiers,
feature transforms, and normalization techniques. For both abstract and sentence classification tasks
we tested several linear classifiers: logistic regression, support vector machines (SVM), binomial Naive
Bayes, linear discriminant analysis, and a modification of the Variable Trigonometric Threshold (VTT)
classifier, previously developed by Rocha’s lab and found to perform well on protein-protein interaction
text mining tasks [12,41,42]. As we describe in the results and discussion sections, classifiers fall into two
main classes based on whether or not they take into account feature covariances. In addition, we compared
different feature transform methods, including normalization techniques such as ‘Term Frequency, Inverse
Document Frequency’ (TFIDF) and dimensionality reduction based on Principle Component Analysis
(PCA). We also compared performance when including features generated by several Named Entity
Recognition (NER) tools and specialized dictionaries.
In the experiments reported, our goal is to measure the quality of automated methods in identifying
pharmacokinetic evidence of DDIs reported in the literature. More generally, we seek to demonstrate
that literature mining can be successful in automatically extracting experimental evidence of interactions
as part of DDI workflows. We show that many classifier configurations achieve high performance on this
task, demonstrating the robustness and efficacy of BLM on extracting pharmacokinetic evidence of DDI.
Materials and Methods
The following sections describe the methods used in our literature mining pipeline. Its basic steps are
visually diagrammed in Fig. 1. They include the selection of corpus documents, hand-labeling of ground
truth assignments, extraction and normalization of textual features, and computation of unigram/bigram
occurrences matrices. Cross-validation folds are used to estimate generalization performance of classi-
fier and feature transform configurations, while nested (inner) cross-validation folds are used to choose
classifier hyperparameters. The software consisted of custom Python scripts unless otherwise noted.
4Figure 1. Literature mining pipeline: The basic steps of the literature mining pipeline include
selection of corpus documents, hand-labeling of ground truth assignments, extraction and normalization
of textual features, and computation of unigram/bigram occurrences matrices. Cross-validation folds
are used to estimate generalization performance of classifier and feature transform configurations, while
nested (inner) cross-validation folds are used to choose classifier hyperparameters.
Abstract Corpus
For the training corpus, Li’s lab selected 1203 pharmacokinetics-related abstracts by searching PubMed
using terms from a previously developed ontology for PK pharmacokinetic parameters [38]. Therefore, all
retrieved articles describe and contain some form of pharmacokinetic evidence, though not necessarily of
DDI. We kept in vitro studies but removed any animal in vivo studies. Abstracts were labeled according
to the following criteria: abstracts that reported the presence or absence of drug interaction supported
by explicit experimental evidence of pharmacokinetic parameter data were labeled as DDI-relevant (909
abstracts) while the rest were labeled as DDI-irrelevant (294 abstracts). DDI-relevance was established
regardless of whether the relevant enzymes were presented or not. Importantly, the concept of DDI-
relevance employed here updates the criteria used in a previous preliminary study [39]. Interactions
between a drug and food, fruit, smoking, alcohol, and natural products are now classified as drug interac-
tions because their pharmacokinetics studies are designed similarly. For the same reason, studies dealing
with interactions between drug metabolites (instead of parent compounds) are now also considered rele-
vant, as well as studies reporting inhibition of induction of a drug on a drug metabolism enzyme or drug
transporter. Classification was done by three graduate students with M.S. degrees and one postdoctoral
annotator; any inter-annotator conflicts were checked by a Pharm D. and an M.D. scientist with extensive
5pharmacological training. The corpus is publicly available as “Pharmacokinetics DDI-Relevant Abstracts
V0” in [43] (see also [26]).
We extracted textual features from PubMed article title and abstract text fields as well as the following
metadata fields: the author names, the journal title, the Medical Subject Heading (MeSH) terms, the
‘registry number/EC number’ (RN) field, and the ‘secondary source’ field (SI) (the latter two fields
contain identification codes for relevant chemical and biological substances). For each PubMed entry,
the content of the above fields was tokenized, processed by Porter stemming [44], and converted into
textual features (unigrams and, in certain runs, bigrams). Strings of numbers were converted into ‘#’,
short textual features (with length of less than 2 characters) and infrequent features (that occurred in
less than 2 documents) were omitted. Author names, journal titles, substance names, and MeSH terms
were treated as single textual tokens.
The corpus was represented as binary term-document occurrence matrices. We evaluated classification
performance under two different conditions: in the first — referred to as ‘unigram runs’ — only word
unigram features were used; in the second — referred to as ‘bigram runs’ — word bigram features were
used in addition to unigram features. Bigram runs included a much larger number of parameters (i.e. the
bigram feature coefficients) that needed to be estimated from training data, which can potentially increase
generalization error arising from increased model complexity [45]. Testing the classifiers exclusively
with unigram features as well as with both unigram and bigram features evaluated whether the class
information provided by bigrams outweighed their cost in complexity.
Sentence Corpus
The evidence sentence task consisted in identifying those sentences within a PubMed abstract that re-
ported experimental evidence for the presence or absence of a specific DDI. For this purpose, Li’s group
developed a training corpus of 4600 sentences extracted from 428 PubMed abstracts. All abstracts con-
tained (positive or negative) pharmacokinetic evidence of DDIs. Sentences were manually labeled as
DDI-relevant (1396 sentences) if they explicitly mentioned pharmacokinetic evidence for the presence or
absence of drug-drug interactions, and as DDI-irrelevant (3204 sentences) otherwise. The same pre-
processing and annotation procedures were followed for the sentence corpus as for the abstract corpus
(see section “Abstract Corpus”). This corpus is publicly available as “Deep Annotated PK Corpus V1”
in [43] (see also [26]).
Classifiers
Six different linear classifiers were tested:
1. VTT : a simplified, angle-domain version of the Variable Trigonometric Threshold Classifier, pre-
viously developed in Rocha’s lab [12,41, 42]. Given a document vector x=<x1,...,xK> with features (i.e.
dimensions) indexed by i, the separating hyperplane is defined as∑
i
ϕixi − λ = 0
Here, λ is a threshold (bias) and φi is the ‘angle’ of feature i in binary class space:
ϕi = arctan
pi
ni
− pi
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where pi is the probability of occurrence of feature i in relevant-class documents and ni is the probability
of occurrence of feature i in irrelevant-class documents. The threshold parameter λ is chosen so that a
neutral ‘pseudo-document’ defined by xi=(pi+ni)/2 falls exactly onto the separating hyperplane.
The full version of VTT, which includes additional parameters to account for named entity occurrences
and which we have previously used in protein-protein interaction classification, is evaluated in combination
6with various NER tools in section “Impact of NER and PubMed metadata on abstract classification”
below. VTT performs best on sparse, positive datasets; for this reason, we do not evaluate it on dense
dimensionality-reduced datasets. Notice that in previous work, we used a different version of VTT with
a cross-validated threshold parameter; its performance on the tasks was very similar, and is reported in
the Supporting Information as the ‘VTTcv’ classifier (section 1 and 2 in S1 Text).
2. SVM : a linear Support Vector Machine with a cross-validated regularization parameter (imple-
mented using the sklearn [46] library’s interface to the LIBLINEAR package [47]).
3. Logistic regression classifier with a cross-validated regularization parameter (also implemented
using sklearn’s interface to LIBLINEAR).
4. Naive Bayes classifier with smoothing provided by a Beta-distributed prior with a cross-validated
concentration parameter.
5. LDA: a regularized Linear Discriminant Analysis classifier, following [48]. Singular value decompo-
sition (SVD), a dimensionality reduction technique, is first used to reduce any rank-deficiency, after which
the covariance matrix is shrunk toward a diagonal, equal-variance structured estimate. The shrinkage
parameter is determined by cross-validation.
6. dLDA: a ‘diagonal’ LDA, where only the diagonal entries of the covariance matrix are estimated
and the off-diagonal entries are set to 0. A cross-validated parameter determines shrinkage toward a
diagonal, equal-variance estimate. This classifier can offer a more robust estimate of feature variances; it
is equivalent to a Naive Bayes classifier with Gaussian features [49].
Generally, linear classifiers fall into one of two types. Classifiers of the first type — sometimes called
‘naive’ in the literature, which in our case include VTT, dLDA, and Naive Bayes — learn feature weights
without considering feature covariances. While covariance information can be useful for distinguishing
classes, naive classifiers often perform well with small amounts of training data, when covariances are
difficult to estimate accurately. Classifiers of the second type — which we refer to as ‘non-naive’, and
which in our case included SVM, LDA, and Logistic Regression — do consider feature covariances (often
in combination with regularization techniques to smooth covariance estimates) and can achieve superior
performance when provided with sufficient training data.
Feature Transforms
For both unigram and bigram runs, we evaluated classification performance on several transforms of the
document matrices:
1. No transform: raw binary occurrence matrices (see section “Abstract Corpus”).
2. IDF: occurrences of feature i were transformed to its Inverse Document Frequency (IDF) value:
idf (i) = log Nci+1 , where ci is the total number of occurrences of feature i among all documents. This
reduced the influence of common features on classification.
3. TFIDF: the Term Frequency, Inverse Document Frequency transform (TFIDF); same as above,
but subsequently divided by the total number of features that occur in each document. This reduced the
impact of document size differences.
4. Normalization: the non-transformed, IDF, and TFIDF document matrices underwent a length-
normalization transform, where each document vector was inversely scaled by its L2 norm. L2 normal-
ization has been argued to be important for good SVM performance [50].
5. PCA: The above matrices were run through a Principal Component Analysis (PCA) dimensionality
reduction step. Projections onto the first 100, 200, 400, 600, 800, and 1000 components were tested.
Feature transforms can improve classification performance by making the surfaces that separate doc-
uments in different classes more linear and by decreasing the weight of non-discriminating features. PCA,
on the other hand, reduces the number of parameters that need to be estimated from training data. If
class membership information is contained in the subspace spanned by the largest principal components,
then this kind of dimensionality reduction can improve generalization performance by reducing noise and
model complexity.
7Performance evaluation
The abstract and sentence corpora described above were used both for training classifiers and for es-
timating generalization performance on out-of-sample documents. In order to estimate out-of-sample
performance, we used the following cross-validation procedure for each possible classifier and feature
transform:
1. Each corpus was randomly partitioned into 4 document folds (75%-25% splits). This was repeated
4 times, yielding 16 outer folds. All classifiers and transforms were evaluated using the same partitions.
2. For each fold, the 75% split was treated as the ‘training’ split and the 25% split was treated as
the ‘testing split’. If a feature transform was used, it was applied to both splits but was computed using
statistics (such as IDF or principal components) from the training split. Finally, classifiers were trained
on the training split and evaluated based on their prediction performance on the testing split.
3. Measures of classification performance (see below) on the testing split were collected. The 16 sets
of performance measures were averaged to produce an estimate of generalization performance.
Because training and testing documents are always separated, for each cross-validation fold the above
procedure is equivalent to calculating performance on an independent testing corpus.
Except for VTT, the classifiers listed in section “Classifiers” used cross-validated regularization pa-
rameters. These parameters were not chosen using cross-validation on the outer folds because this would
lead to a biased estimate of out-of-sample performance. Instead, regularization parameters were chosen
using nested cross-validation within each of the 75% blocks of the above outer folds:
1. The 75%-block was itself partitioned into 4 folds (75%-25% splits of the outer 75% block). This is
repeated 4 times, producing a total of 16 inner folds for each outer fold training split.
2. Over a range of values of the cross-validated parameter, the procedure described in step 2 above
was used, but now applied to the 75%/25% splits of each inner fold. Mean performance on inner fold
testing splits were measured using the Matthews Correlation Coefficient [51] (MCC), which is particularly
well-suited for the unbalanced scenarios of our corpora [52].
3. The parameter value giving the highest mean MCC was chosen as the regularization parameter
value for training the classifier in the outer fold.
We evaluated the performance of the classifiers using three different measures: the balanced F1 score
(the harmonic mean of precision and recall), the iAUC or ‘area under the interpolated precision/recall
curve’ [53], and the MCC. In addition, we computed and reported the rank product of these three
measures (RP3) as a single inclusive metric of classification performance. The RP3 measure provides a
well-rounded assessment of classifier performance, as it combines the ranking of the different individual
measures [12,41].
For displaying results, we focus primarily on the iAUC measure (in cases where only plots of iAUC
performance are provided, F1 and MCC plots are found in the Supporting Information, S1 Text). iAUC
does not depend on predicted class assignments but rather on the ranking of test set documents ac-
cording to classifier confidence scores from most relevant to most irrelevant. iAUC offers three major
advantages as a measure of classification performance. First, it provides a more comprehensive measure
of classifier performance because it evaluates the entire ranking of documents, as opposed to just class
assignments. Second, iAUC is less sensitive to variation driven by random-sampling differences in the
training corpus, which may lead to fluctuations in the class assignments of low confidence documents
and, correspondingly, high variability in measures such as F1 and MCC. Finally, it is more relevant
in a frequently-encountered situation where a human practitioner uses a BLM pipeline to retrieve only
the most relevant documents (which should have high positive-class confidence scores) or to identify
likely-to-be-misclassified documents (which should have low confidence scores).
Both the abstract and sentence classification tasks are characterized by imbalanced datasets, with
more relevant-class abstracts and more irrelevant-class sentences respectively. For simplicity, and because
we are primarily concerned how ranking performance (as measured by iAUC) changes between different
machine learning configurations on the same dataset, we do not perform resampling or re-weighting
8of training items. We also report MCC values, a measure which is known to be stable in the face of
unbalanced classes [52].
The performance of a classifier and feature transform configuration varies both due to random sampling
of folds and due to the inherent performance bias of the configuration over the entire distribution of folds.
Since we are only interested in the latter, observed performance differences between pairs of configurations
were tested for statistical significance using a non-parametric paired-sample permutation test. First,
the assignments of performance scores for each of the 16 outer folds were permuted between the two
classifier/transform configurations under consideration. For each of the 216 possible permutations, the
difference in across-fold mean performance was calculated; this formed the distribution of performance
differences under the null hypothesis that the two configurations have equal performance. Finally, the
p-value was computed as the probability (one- or two-tailed, as indicated) of observing a difference under
the null hypothesis distribution equal to or greater than the actual difference.
Results
Abstract classification performance
Fig. 2 shows classifier performance on the abstract task for the unigram and bigram runs with no feature
transform applied. The best classifier configuration, as well as those configurations not significantly
different from the best (p>0.05, one-tailed test), are marked with an asterisk. In addition, the performance
results, ranks, and the rank-product (RP3) measure are reported in Table 1. The best classifier achieves
F1≈0.93, iAUC≈0.98, MCC≈0.73, which constitutes a substantial and significant improvement over our
previous preliminary results reported in [39], where we had reached F1≈0.8, iAUC≈0.88, MCC≈0.6
(notice that these performance values would be well below the lowest reported levels in Fig. 2). This
demonstrates that the corpus used in this work — which is more carefully curated and now also considers
interactions between drugs and food, fruit, smoking, alcohol, and natural products to be relevant (details
in “Materials and Methods Section”) — improves the classification of abstracts with pharmacokinetic
evidence of DDI. The levels of performance achieved are excellent when compared to similar abstract
classification tasks in other biomedical domains. For instance, in the BioCreative Challenge III, considered
one of the premier forums for assessment of text mining methods, the best classifiers of abstracts with
Protein-Protein Interaction yielded performances of F1≈0.61, iAUC≈0.68, MCC≈0.55 [17]. Naturally,
our results are not directly comparable to results obtained on different corpora and on a different problem;
rather, these numbers provide guidance on what is typically considered good results in biomedical article
classification.
9Figure 2. Classification performance on abstracts: Performance for both unigram and bigram
runs on non-transformed features. Left: F1 measure. Middle: MCC measure. Right: iAUC measure.
The best classifier configuration, and configurations not significantly different (p>0.05, one-tailed test)
from it, marked with asterisk ‘*’.
Classifier Type F1 MCC iAUC RP3
LDA Bigram .931 (1) .728 (1) .984 (1) 1
Log Reg Bigram .929 (2) .698 (3) .984 (1) 6
SVM Bigram .928 (3) .693 (4) .983 (3) 36
LDA Unigram .926 (6) .719 (2) .983 (3) 36
Log Reg Unigram .927 (4) .689 (5) .980 (6) 120
SVM Unigram .927 (4) .689 (5) .980 (6) 120
Naive Bayes Bigram .920 (7) .661 (10) .981 (5) 350
Naive Bayes Unigram .919 (8) .672 (7) .978 (9) 504
VTT Bigram .919 (8) .656 (12) .980 (6) 576
VTT Unigram .918 (10) .662 (9) .977 (10) 900
dLDA Bigram .909 (11) .670 (8) .975 (11) 968
dLDA Unigram .908 (12) .658 (11) .974 (12) 1584
Table 1. Classification performance on abstracts: Performance for both unigram and bigram
runs on non-transformed features according to F1, MCC, and iAUC performance measures. The rank of
the classifiers according to each measure is reported in parenthesis in the respective column. Classifiers
are ordered according to the rank product (RP3) of the three measures (last column).
For each classifier, the inclusion of bigram features improved performance according to the RP3
measure. The best classifier according to all measures was LDA using bigrams. The performance of this
classifier was significantly better than all others for the MCC, but not significantly better that Logistic
Regression according to iAUC, and not significantly better that Logistic Regression and SVM according to
F1 score. According to RP3, these three classifiers using bigrams yield the best performance. Naive Bayes,
VTT, and dLDA— classifiers that make a ‘naive’ independence assumption about features (see “Materials
and Methods” section) — performed below the top three. However, the performance levels they achieved
are still quite high, which indicates that such simple classifiers are also capable of classifying documents
with pharmacokinetic DDI evidence in our corpus. The in-house VTT classifier is the only classifier
among these that does not use cross-validated parameters; when used with NER features and cross-
validated parameters (the configuration for which it was originally designed [12,41,42]), its performance
improved (see below).
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Feature Transforms and Dimensionality Reduction
The different feature transforms and PCA-based dimensionality reductions (section “Materials and Meth-
ods”) significantly improved performance for several classifiers, though they could not beat the perfor-
mance of the best non-transformed classifier. Details are provided in Supporting Information (section
1.1 in S1 Text). To summarize, according to most measures only dLDA and SVM improved performance
significantly with either an IDF or TFIDF transform plus L2 normalization and dimensionality reduction
(top n principal components). For instance, the best iAUC for SVM (0.984) occurs with a dimensionality
reduction to the top 800 principal components and no feature transform; this is a significant improvement
over the no-transform, no dimensionality reduction SVM classifier reported in Table 1 and Fig. 2, but not
a significant improvement over the overall best classifiers reported there (LDA and Logistic regression).
The dLDA classifier significantly improves its iAUC performance with almost all feature transform and
dimensionality reduction combinations, but not above that of the top performing classifiers. We conclude
that feature transforms and dimensionality reduction does not lead to the best classification performance
on the abstract task.
Pharmacokinetics DDI Features in abstract classification
We looked at which textual features play the largest role in the abstract classification task. A linear
classifier separates document classes with a hyperplane defined by a set of feature coefficients. The
impact of a feature on classification is quantified by the sign and amplitude of its hyperplane coefficient. A
feature with a large positive coefficient contributes strongly to a document’s propensity to be classified as
relevant, while a feature with a large negative coefficient contributes strongly to a document’s propensity
to be classified as irrelevant. In Table 2, we show the top 20 most distinctive features of the relevant
and irrelevant classes in the abstract task, as chosen in the bigrams runs by the LDA classifier (left) and
Logistic Regression classifier (right), the two top-performing classifiers in this task according to the RP3
measure (see Table 1). Notice that textual features are stemmed.
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Relevant Irrelevant
MeSH:Drug Interactions area
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decreas higher
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treatment patient
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Logistic Regression (Bigram)
Relevant Irrelevant
MeSH:Drug Interactions area
interact rate
inhibit differ
interact between MeSH:Reference Values
oral activ
decreas that the
mg conclus
Substance:Enzyme Inhibitors clearanc of
receiv higher
auc patient
determin MeSH:Female
treatment patient with
day MeSH:Injections, Intravenous
inhibitor polymorph
chang genotyp
dure MeSH:Phenotype
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administ MeSH:Half-life
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Table 2. Top 20 relevant and irrelevant abstract features: The stemmed textual features most
discriminative of relevant and irrelevant classes on the abstract task, as chosen by two of the
top-performing classifiers according to the RP3 measure: LDA with bigrams (left) and Logistic
Regression with bigrams (right).
Some of the most relevant features come from MeSH term metadata (such as the MeSH term Drug
interactions) and terms that explicitly indicate interactions (‘interact’, ‘inhibit’, ‘interact between’, ‘de-
creas’, ‘increas’). Other relevant terms deal with administration protocols and study design (‘oral’, ‘day’,
‘receiv’, ‘mg’, ‘treatment’, ‘alon’, ‘combin’). Some of the irrelevant features concern genetics terminology
(‘allel’, ‘genotyp’, ‘polymorph’, and MeSH term Phenotype), indicating that the irrelevant class was en-
riched with genetics or pharmacogenetics vocabulary. Several generic biomedical terms (such as ‘patient’,
‘healthi subject’, ‘higher’) terms are also highly irrelevant. In addition, highly irrelevant features also
contain some non-DDI-specific pharmacokinetic terms (for example, ‘area’, ‘rate’, ‘clearance of’), which is
not surprising given that both relevant and irrelevant articles were drawn from pharmacokinetics-related
literature. One surprising result is the observation that while the MeSH term Male is one of the top
relevant features, the MeSH term Female is one of the top irrelevant features. We have no explanation
for the cause of this gender imbalance since the corpus was built from automatic searches to PubMed
without any gender-specific query terms.
Further analysis of highly relevant and irrelevant features across all classifiers and feature transforms
was performed and reported in the Supporting Information (section 1.2 in S1 Text). We quantified
and plotted the contribution of standardized coefficients [54] of different features and show the most
positively and negatively loaded features for different classifier and transform configurations. Top tex-
tual features obtained from all classifiers include additional terms falling under the categories described
above, with features derived from PubMed metadata (MeSH, chemical substances) also appearing among
both the most relevant and irrelevant sets. Other relevant MeSH terms, besides Drug Interactions, in-
clude Cimetidine/pharmacology, Cross-Over Studies, Enzyme Inhibitors/PK, Kinetics, and Proton Pump
Inhibitors. Additionally, a PubMed author entry corresponding to a prominent researcher in the phar-
macokinetics DDI field (‘PJ Neuvonen’) appears as highly relevant, as well as three substances from
the RN field (see also section “Impact of NER and PubMed metadata on abstract classification” below):
Cimetidine, Enzyme Inhibitors, and Proton Pump Inhibitors. For the irrelevant set, additional MeSH
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(Anti-Ulcer Agents/adm&dos; Injections, Intravenous; Phenotype; Protein Binding ; Reference Values)
and Substance terms also appear (Anti-ulcer agents; Hydrocarb. Hydroxylas). The Supporting Informa-
tion S1 Text contains details of the analysis and lists of features. It also shows the results of a Principal
Component Analysis of feature weight coefficients chosen by different classifiers.
Impact of NER and PubMed metadata on abstract classification
We have previously demonstrated improved classification performance on protein-protein interaction BLM
tasks by supplementing textual features (such as the word unigram and bigram occurrences) with features
built using Named Entity Recognition (NER) and domain-specific dictionary tools [12, 41, 42]. To test
if similar techniques are useful in the DDI domain, we counted mentions of named biochemical species
(e.g. proteins, compounds and drugs) and concepts (e.g. pharmacokinetic terms) in each document
and then included these counts as document features in addition to the bigram and unigram textual
features. Counts were extracted using biomedical-specific NER extraction tools and dictionaries, with
dictionary matches identified by internally-developed software. A preliminary study of the impact of
NER/Dictionary features was reported in [39] using a previous less-refined DDI corpus. Here, in addition
to using the more fine-tuned corpus (see “Methods and Data” section), we study the impact of PubMed
metadata features on classification performance. We also provide a new comprehensive analysis of the
performance impact of including features from several publicly-available NER and metadata resources:
• OSCAR4 [55]: NER tool for chemical species, reaction names, enzymes, chemical prefixes and
adjectives.
• ABNER [56]: NER tool for genes, proteins, cell lines and cell types.
• BICEPP [57]: NER tool for clinical characteristics associated with drugs.
• DrugBank database [58]: a dictionary list of drug names
• Dictionaries provided by Li’s lab. i-CYPS : cytochrome P450 [CYP] protein names, a group of
enzymes centrally involved in drug metabolism; i-PkParams: terms relevant to pharmacokinetic
parameters and studies; i-Transporters: proteins involved in transport; i-Drugs: Food and Drug
Administration’s drug names. The dictionaries are available for download from [43].
For each of these NER tools and dictionaries, we counted the number of occurrences of any of its en-
tities/entries in a given abstract. These counts were treated as any other feature for SVM, Logistic
Regression, diagonal LDA, and LDA classifiers. Naive Bayes was omitted since NER count features are
non-binary. VTT incorporates NER features via a modified separating hyperplane equation:∑
i
ϕixi −
∑
j
βj − cj
βj
− λ = 0
where xi represents the occurrence of textual feature i, φi and λ are textual feature and bias parameters
as described in section “Classifiers”, cj is the count of NER/Dictionary feature from resource j, and βj is
a weight for resource j, which is chosen by cross-validation.
In Fig. 3 (left), we plot the relative iAUC changes over the respective classifiers without
NER/Dictionary count features (results for MCC and F1 in Supporting Information; section 1.3 in S1
Text). Significant performance changes are indicated with an asterisk (p<0.05, two-tailed test). Some
NER/Dictionary features improved performance significantly for several classifiers. However, the inclu-
sion of two dictionary features (DrugBank, and i-CYPS ) actually decreased performance significantly for
several classifiers, suggesting that these features contain little class information and instead contribute to
over-fitting. Table 3 lists performance for configurations in which NER and dictionary features gave a sig-
nificant performance increase for at least one of the three measures (F1, MCC, or iAUC), along with best
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classifier performance using only textual features (bigram runs). The BICEPP tool consistently yielded
the best improvement for every classifier tested, followed by the i-Drugs dictionary. The OSCAR4 tool
also significantly improved the performance of the VTT classifier (especially for the MCC measure as
shown in Supporting Information, S1 Text). With the inclusion of NER and dictionary features, the over-
all top classifiers (LDA and Logistic Regression), significantly improved their performance, now reaching
F1≈0.93, MCC≈0.74, iAUC≈0.99. Among the set of naive classifiers, VTT improved performance sig-
nificantly with the inclusion of NER features, ranking above the other naive classifiers according to the
RP3 measure.
Figure 3. Performance impact of abstract NER and metadata features: Left: Relative
changes in iAUC scores on non-transformed bigram runs in combination with different NER/Dictionary
features. Significant changes (p<0.05, two-tailed test) in performance over the respective classifiers
without NER features are indicated with asterisk ‘*’. Right: Relative changes in iAUC when features
from a given PubMed metadata field are included versus omitted (while including features from the
other 4 metadata fields). Significant changes (p<0.05, two-tailed test) in performance are indicated
with asterisk ‘*’.
14
Classifier NER F1 MCC iAUC RP3
LDA BICEPP .933 (2) .737 (1) .985 (1) 2
LDA i-Drugs .934 (1) .736 (2) .985 (1) 2
Log Reg BICEPP .933 (2) .714 (3) .985 (1) 8
Log Reg i-Drugs .930 (6) .700 (6) .985 (1) 36
LDA − .931 (5) .728 (3) .984 (5) 75
SVM BICEPP .932 (4) .710 (5) .984 (5) 100
Log Reg − .929 (8) .698 (7) .984 (5) 280
SVM i-Drugs .930 (6) .687 (10) .984 (5) 300
SVM − .928 (9) .693 (8) .983 (9) 648
VTT BICEPP .922 (11) .692 (9) .980 (12) 1188
VTT OSCAR4 .923 (10) .683 (11) .979 (14) 1540
VTT i-Drugs .920 (12) .670 (14) .981 (10) 1680
Naive Bayes − .920 (12) .661 (16) .981 (10) 1920
dLDA BICEPP .911 (15) .680 (12) .976 (15) 2700
VTT − .919 (14) .656 (17) .980 (12) 2856
dLDA i-Drugs .911 (15) .678 (13) .975 (16) 2700
dLDA − .909 (17) .670 (14) .975 (16) 3808
Table 3. Abstract classification performance using NER features: Performance of the best
classifiers when specific NER and dictionary features are added; original (bigram runs) classifiers also
listed with no NER features (indicated by -). F1, MCC, and iAUC performance measures are listed; the
rank of the classifiers according to each measure is reported in parenthesis in the respective column.
Classifiers are ordered according to the rank product (RP3) of the three measures (last column).
As mentioned, word unigram and bigram features were extracted not only from article abstracts and
titles, but also from five PubMed metadata fields: author names, journal titles, MeSH terms, and two
fields referring to standardized substance names: the ‘registry number/EC number’ [RN] field and the
‘secondary source’ field [SI]. In fact, some PubMed metadata features were among those most distinguish-
ing of relevant and irrelevant abstracts (for greater detail, see Table 2 and section “Pharmacokinetics DDI
Features in abstract classification”, as well Supporting Information; section 1.2 in S1 Text). We tested the
impact of PubMed metadata fields on abstract classification performance. In Fig. 3 (right), we plot the
relative iAUC changes when features from a given PubMed metadata field are included versus omitted
(while including features from the other 4 metadata fields). Significant changes (p<0.05, two-tailed test)
in performance are indicated with an asterisk; results for MCC and F1 can be found in Supporting In-
formation (S1 Text). MeSH terms was the only metadata source whose omission decreased performance
significantly. However, the performance increase of including MeSH data is rather small. Therefore, the
methodology does not require the availability of human-annotated metadata such as MeSH terms and
can still be deployed on recent articles that have not yet been annotated with MeSH terms.
Evidence sentence extraction performance
Fig. 4 shows classification performance on the sentence task of the unigram and bigram runs without any
feature transforms applied, according to F1, MCC, and iAUC measures. The best classifier configuration,
as well as those configurations not significantly different from the best (p>0.05, one-tailed test), are
marked with an asterisk. In addition, the numerical results, ranks, and the rank-product (RP3) measure
are reported in Table 4.
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Figure 4. Sentence classification performance: Performance for both unigram and bigram runs
on non-transformed features. Left: F1 measure. Middle: MCC measure. Right: iAUC measure. The
best classifier configuration, and configurations not significantly different (p>0.05, one-tailed test) from
it, marked with asterisk ‘*’.
Classifier Type F1 MCC iAUC RP3
LDA Bigram .752 (1) .642 (1) .826 (1) 1
LDA Unigram .750 (2) .636 (2) .819 (4) 16
SVM Bigram .736 (3) .633 (3) .824 (2) 18
Log Reg Bigram .734 (7) .630 (4) .823 (3) 84
SVM Unigram .735 (6) .630 (4) .819 (4) 96
VTT Bigram .736 (3) .617 (8) .797 (7) 168
Naive Bayes Unigram .736 (3) .617 (8) .791 (10) 240
Log Reg Unigram .734 (7) .629 (6) .818 (6) 252
Naive Bayes Bigram .734 (7) .619 (7) .796 (8) 392
dLDA Unigram .732 (11) .613 (10) .790 (11) 1210
dLDA Bigram .710 (12) .600 (12) .794 (9) 1296
VTT Unigram .733 (10) .606 (11) .789 (12) 1320
Table 4. Sentence classification performance: Performance for both unigram and bigram runs on
non-transformed features according to F1, MCC, and iAUC performance measures. The rank of the
classifiers according to each measure is reported in parenthesis in the respective column. Classifiers are
ordered according to the rank product (RP3) of the three measures (last column).
As with abstracts, including bigram features tended to improve sentence classification performance.
LDA performed best, having the highest RP3 and being the best classifier according to the F1 and MCC
measures and one of the two best classifiers (along with SVM) on the iAUC measure. Generally, the
classifiers that performed well on the sentence task were those that took into account feature covariances:
SVM, Logistic Regression, and LDA. The top classifier (LDA with bigrams) on the evidence sentence
task reached performance of F1≈0.75, MCC≈0.64, iAUC≈0.83.
We measured sentence classification performance in combination with different feature transforms
and dimensionality reductions (see section 2.1 in Text S1). In general, the three classifiers that do
best on non-transformed features (SVM, Logistic Regression, and LDA) show decreased performance
with dimensionality reduction according to all measures, with more extreme dimensionality reduction
leading to larger performance decreases. On the other hand, for dLDA (a ‘naive’ classifier that treats
features as independent), PCA-based dimensionality reduction — which uses feature covariances to choose
optimal projections — led to significant improvements in all measures, with more dimensions giving better
performance. These findings indicate that the pattern of feature covariance carries important information
about class membership in the sentence task, and that this pattern is distributed across a large number of
dimensions. Generally, the LDA classifier achieved the best performance according to all three measures.
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Its baseline performance according to the iAUC measure was further improved significantly by an IDF-
transform, and — according to the F1 measure — by any transform containing an L2 normalization.
In Table 5, we show the top 20 features most distinctive of the relevant and irrelevant classes in
the sentence task as chosen by the LDA classifier on bigrams (the top performing classifier according
to the RP3 measure; features of other top classifiers are not shown because they were highly similar).
Numerical features (indicated by ‘#.#’) were highly indicative of the relevant class, along with expressions
of quantitative changes (‘decreas’, ‘increas’) and interaction (‘inhibit’, ‘catalyz’, ‘interact with’) as well
as adverbs expressing significance of evidence (‘significantli’). Also highly relevant were features referring
to the area under the concentration-time curve (‘auc’), which is often employed in pharmacokinetics to
measure differences in drug clearance rates under different experimental conditions. Names of several
drugs (‘ketoconazol’, ‘itraconazol’, ‘quiindin’) were relevant in predicting DDI evidence sentences. These
drugs are frequently used probe inhibitors for metabolism enzymes CYP3A4/5, CYP3A4/5 and CYP2D6
respectively and are routinely used in drug interaction studies.
LDA (Bigram)
Relevant Irrelevant
inhibit day
increas investig
#.# determin
ketoconazol vitro
decreas evalu
microm enzym
rifampin use
format differ
catalyz cytochrom p450
auc studi
significantli dose
coadministr examin
itraconazol measur
quinidin subject
clearanc assess
reduc interact
#.#-fold compar
show drug
co-administr genotyp
interact with cytochrom
Table 5. Top 20 relevant and irrelevant sentence features: The most discriminative features of
relevant and irrelevant classes in the sentence task, as chosen by the top-performing classifiers according
to the RP3 measure: LDA on bigrams.
Highly irrelevant features refer to more generic pharmacokinetic or biomedical concepts such as ‘in-
vestig’, ‘dose’, ‘enzym’, ‘studi’, etc. Interestingly, some terms that are highly relevant in the abstract task
are highly irrelevant in the sentence task (e.g., ‘day’). Notably, the unigram ‘interact’ is highly irrelevant
for sentences, whereas the bigram ‘interact with’ is highly relevant. This may be because all sentences in
this corpus come from abstracts containing pharmacokinetic DDI evidence (see “Materials and Methods”
section). Thus, general administration protocols and drug interaction terms are likely to occur in the
abstract as a whole but not necessarily in the evidence sentences that actually report outcomes of the
pharmacokinetic drug interaction experiments. Similar patterns are observed in the more extensive anal-
ysis provided in Supporting Information (section 2.2 in S1 Text), where relevant and irrelevant features
are analyzed across a wide range of classifier and feature transform configurations. There we also show
the results of a Principal Component Analysis of feature weight coefficients chosen by different classifiers.
Finally, we tested the impact of additional features on sentence classification. Though there is no
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metadata available in the sentence corpus, features from NER tools can still be computed. Six NER
features were tested: BICEPP, DrugBank, i-CYPS, i-Drugs, i-PkParams, i-Transporters (see section
“Impact of NER and PubMed metadata on abstract classification” for details). As before, we counted
mentions of named biochemical species and concepts specified by different NER tools in each sentence and
then included such counts as sentence features in addition to the bigram and unigram textual features.
Fig. 5 shows relative iAUC changes when features from each of these NER tools were included. Significant
improvements (p<0.05, two-tailed test) above the corresponding classifier’s performance without NER
features are indicated by an asterisk; performance according to MCC and F1 measures is shown in
Supporting Information (section 2.3 of S1 Text). Notice that Naive Bayes was omitted since NER count
features are non-binary.
Figure 5. Performance impact of sentence NER features: Relative changes in iAUC scores on
sentence bigram runs (without transforms or dimensionality reductions) in combination with different
NER features. Significant changes (p<0.05, two-tailed test) in performance over respective classifiers
without NER features are indicated with asterisk ‘*’.
As in the abstract task, a few NER/Dictionary features improved performance for several classifiers.
The iAUC scores of nearly all classifiers were significantly improved by three NER features: BICEPP,
DrugBank, and our internally developed i-Drugs dictionary. These three features represent counts of
drugs names, showing that drug name counts are helpful for classifying sentences as DDI-relevant vs.
DDI-irrelevant. Use of features from the BICEPP tool yielded the largest improvement for every classi-
fier. Table 6 lists the performance according to all measures for classifiers using the BICEPP features;
also listed are the corresponding best classifiers using only textual features (bigram runs). The overall
top classifiers (LDA and SVM) showed significantly improved performance with the inclusion of these
NER features, reaching F1≈0.76, MCC≈0.65, iAUC≈0.83. In addition, VTT performance improved sig-
nificantly for all three measures with the inclusion of NER features. Here VTT with bigrams performs
better than other naive classifiers, as expected given that this classifier was designed specifically to handle
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such NER features [12, 41, 42]. In contrast, dLDA (another naive classifier) did not benefit much from
the inclusion of NER features.
Classifier Type F1 MCC iAUC RP3
LDA BICEPP .757 (1) .650 (1) .831 (1) 1
SVM BICEPP .741 (4) .639 (3) .831 (1) 12
LDA − .752 (2) .642 (2) .826 (4) 16
Log Reg BICEPP .738 (5) .634 (4) .828 (3) 60
VTT BICEPP .742 (3) .629 (7) .805 (7) 147
SVM − .736 (6) .633 (5) .824 (5) 150
Log Reg − .734 (8) .630 (6) .823 (6) 288
VTT − .736 (6) .617 (8) .797 (8) 432
Naive Bayes − .734 (8) .619 (8) .796 (10) 640
dLDA BICEPP .711 (10) .603 (10) .797 (8) 800
dLDA − .710 (11) .600 (11) .794 (11) 1331
Table 6. Sentence classification performance with NER features: Performance of different
sentence classifiers with the count features obtained via the BICEPP NER tool; also listed are the
corresponding best classifiers using only textual features (bigram runs; indicated by -). F1, MCC, and
iAUC performance measures are listed; the rank of the classifiers according to each measure is reported
in parenthesis in the respective column. Classifiers are ordered according to the rank product (RP3) of
the three measures (last column).
Discussion
We have demonstrated that current BLM methods for text classification can reliably identify PubMed ab-
stracts containing pharmacokinetic evidence of drug-drug interactions, as well as extract specific sentences
that mention such evidence from relevant abstracts. The performance reached on a corpus of carefully
annotated pharmacokinetics literature is quite high for both abstract classification (reaching F1≈0.93,
MCC≈0.74, iAUC≈0.99) and evidence sentence extraction (F1≈0.76, MCC≈0.65, iAUC≈0.83). To ex-
plore the capability of BLM in the pharmacokinetics DDI context, where there are no existing directly-
relevant corpora or experiments, we pursued a thorough comparison of the performance of several linear
classifiers using different combinations of unigrams, bigrams, PubMed metadata, and NER features. We
also tested the effects of applying feature transforms and dimensionality reduction.
From a classification performance perspective, some results are noteworthy: in terms of textual fea-
tures, bigrams in combination with unigrams performed significantly better than unigrams alone. How-
ever, performance in unigram versus bigram runs for the same classifier differed by no more than one
percent for iAUC and MCC. Thus, while bigram features did contain some additional information about
class membership, the amount of this information was not large.
In our experiments, feature transforms and PCA-based dimensionality reduction significantly im-
proved performance for several classifiers (especially “naive” classifiers such as dLDA, which assume
feature independence), but did not significantly improve the overall best performance. We also found
that a sophisticated version of the LDA classifier dominated performance in both the abstract and sen-
tence tasks. This classifier used SVD to eliminate rank-deficiency in the feature occurrence matrices and
performed shrinkage of the feature covariance matrix for regularization (see “Materials and Methods”).
From the drug-interaction domain perspective, feature analysis in the abstract task revealed that
pharmacokinetic DDI evidence in the literature is highly correlated with terms that explicitly indicate
interaction (including MeSH terms), enzyme inhibitors (including substance names via the RN metadata
field in PubMed), DDI administration protocols, and study design. At the sentence level, drug interaction
evidence from a pharmacokinetics perspective is highly correlated with terms that express experimental
results, such as numerical values, measures of drug clearance, expressions of quantitative changes, as
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well as adverbs expressing significance of evidence. Feature analysis at the abstract level also revealed
that lack of DDI evidence in the pharmacokinetics literature (irrelevant class) is highly correlated with
some terms from PubMed metadata fields, as well as those pertaining to genomic or general medical
terminology. At the sentence level, sentences in relevant abstracts but without DDI evidence tend to
include terminology relevant to pharmacokinetics protocols, as well as more generic interaction discourse
or biomedical concepts.
Since many important features came from PubMed metadata fields, we looked at changes in iAUC
scores when features from different PubMed metadata fields were omitted. We found that only the
omission of MeSH terms significantly affected abstract classification performance. Nonetheless, while
statistically significant, the drop in performance was rather small (affecting only millesimals of the iAUC,
iAUC≈0.98 without), indicating that abstract classification does not depend strongly on the inclusion
of MeSH term features. This is an important consideration since MeSH terms may not be immediately
added to publications, with statistics indicating that only 50% of citations are annotated within 60 days
of inclusion in PubMed [59]. Therefore, classification and evidence extraction from brand new articles
should not rely on such metadata.
We also tested the effect of including features extracted using named entity recognition (NER) and
dictionary tools, namely those for detecting possibly-relevant chemical, genomic, metabolomic, drug, and
pharmacokinetic entities. Generally, dictionaries like BICEPP, i-Drugs, and DrugBank, which counted
the number of times drug names appeared, significantly improved performance for several classifiers on
both the abstract classification and evidence sentence extraction tasks (an exception to this was the lack of
improvement on abstracts when including DrugBank features, an effect that needs further investigation).
Nonetheless, as for MESH term features in abstract classification, the resulting performance increases
were modest, even if statistically significant. This again demonstrates that relevant-class information
can be extracted from abstracts and sentences using solely the statistics of unigram and bigram textual
features.
Notably, relevant and irrelevant documents and sentences both derive from the pharmacokinetics
literature and therefore share similar feature statistics. This makes distinguishing between them a non-
trivial text classification problem, though also a more practically relevant one (e.g. for a researcher who
needs to automatically label potentially relevant documents retrieved from PubMed). Nonetheless, sev-
eral classifiers reached high performance; for example, the abstract ranking performance (iAUC≈0.99)
has little room for further improvement, though the classification performance — while high for this type
of problem — can still be improved.
We observed that many different pipeline configurations reached near-optimal performance. Even
though some performance differences between configurations were statistically significant, they were small.
For instance, iAUC differences between best and worst classifiers varied by no more than 1 percent in the
abstract task and 5 percent in the sentence task. This demonstrates that classification performance in our
experiments was robust to the classifier utilized, and that a BLM pipeline for this problem would do sim-
ilarly well independently of classifier chosen. In particular, while “non-naive” classifiers (which consider
feature covariances) performed better than naive classifiers, the latter are still capable of competitive
performance. These results suggest a fundamental limit on the amount of statistical signal present in the
labels and feature distributions of the corpora as extractable by linear classifiers. However, it is worth
noticing that an analysis of both abstract- and sentence-trained feature weight coefficients shows system-
atic differences between weights selected by naive and non-naive classifiers (see Supporting Information,
S1 Text), indicating that different classifiers emphasize distinct semantic features. Furthermore, it is
possible that performance could be improved by the use of non-linear classifiers or features produced by
more finely DDI-tuned NER tools, relation extraction or NLP methods, or other sophisticated feature-
generation techniques. Indeed, the larger performance variation observed in the sentence task suggests
that sentence extraction performance may improve with larger amounts of training data (which would
permit better estimates of feature covariances).
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It is not trivial to compare our performance results with those previously reported in the literature.
First, there is no gold standard for DDI evidence sentence extraction, especially for a specific evidence-
type such as pharmacokinetics. Second, most sentence extraction tasks in the biomedical domain involve
extraction of passages which can contain several sentences (e.g. the protein-protein interaction subtask in
Biocreative II) or passages relevant for a set of specific targets (e.g. Gene Ontology annotations for specific
gene names in Biocreative I [60] and IV [61]). Due to these difficulties, the performance on those tasks has
been comparatively low, e.g. in BioCreative IV the best F1 score in the gene ontology evidence extraction
task was 0.27 [61] (in Biocreative II, due to possible overlap and multiple accepted passages, the preferred
performance measure was the mean reciprocal rank which reached 0.87 [12, 62]). Considering that our
performance on the sentence task is higher than what is typically reported for the abstract classification in
the biomedical domain (e.g. PPI abstract classification in the BioCreative Challenge III reached F1≈0.61,
MCC≈0.55, iAUC≈0.68 [17]), the classifiers trained on our sentence corpus reached a very good level of
performance, indicating that the corpus is well annotated and that the task is highly feasible. Given the
performance of our approach in extracting pharmacokinetic evidence, the classification methodology and
associated corpus may be useful in the previously explored task of extracting interacting drug pairs from
the literature. For example, it may be more effective to first identify DDI sentences containing specific
types of evidence and then extract the interacting drug names from them, using automated methods or
human expertise tailored to that specific type of DDI evidence.
To conclude, we provide a thorough report of the capability of linear classifiers to automatically
extract pharmacokinetics evidence of DDI from an abstract- and sentence-level annotated corpus. Given
the high performance observed on both abstract and sentence classification for all classifiers, including
the simplest ones, we conclude that under realistic classification scenarios automatic BLM techniques can
identify PubMed abstracts reporting DDI backed by pharmacokinetic evidence, as well as extract evidence
sentences from relevant abstracts. These results are important because pharmacokinetic evidence can be
essential in identifying causal mechanics of putative DDI and as input for further pharmacological and
pharmaco-epidemiology investigation. More generally, our work shows that BLM can be safely included
in DDI discovery pipelines where attention to distinct types of evidence is necessary. In future work, we
intend to use our methodology to mine large corpora for both pharmacokinetic and other types of DDI
experimental evidence. Such evidence can help fill knowledge gaps that exist in the DDI domain, with
the ultimate goal of reducing the incidence of adverse drug reactions and contributing to the development
of alternative safe treatments.
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1 Abstract performance
The following table lists classification performance according to F1, MCC, iAUC, and Accuracy measures
for different classifiers on unigram and bigram abstract runs. It includes the VTTcv classifier (VTT with a
cross-validated threshold), which is not discussed in the main article.
Classifier Type F1 MCC iAUC Accuracy
Log Reg Bigram .929 .698 .984 .891
Log Reg Unigram .927 .689 .980 .888
Naive Bayes Bigram .920 .661 .981 .878
Naive Bayes Unigram .919 .672 .978 .878
SVM Bigram .928 .693 .983 .890
SVM Unigram .927 .689 .980 .888
VTTcv Bigram .916 .697 .980 .877
VTTcv Unigram .911 .663 .977 .868
dLDA Bigram .909 .670 .975 .868
dLDA Unigram .908 .658 .974 .865
LDA Bigram .931 .728 .984 .897
LDA Unigram .926 .719 .983 .891
VTTcv Bigram .916 .697 .980 .877
VTTcv Unigram .911 .663 .977 .868
VTT Bigram .919 .656 .980 .876
VTT Unigram .918 .662 .977 .876
1
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1.1 Abstract performance: Feature transforms and dimensionality reduction
The following charts show iAUC, F1, and MCC performance on abstract bigram runs when feature trans-
forms and dimensionality reductions are applied. Stars indicate configurations that performed significantly
better (p<0.05, one-tailed test) than the no-transform, no-dimensionality-reduction configuration of the same
classifier (indicated with larger circles). Naive Bayes was not tested since it is only applicable to binary data,
and VTT was only tested on the sparse transforms (i.e., without PCA-based dimensionality reduction).
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1.2 Abstract Performance: Most relevant and irrelevant features
A linear classifier separates classes using a hyperplane defined by a set of feature coefficients. The impact of a
given feature on classification is naturally quantified by the sign and amplitude of its hyperplane coefficient.
The increase of the value of a feature with a large positive (negative) coefficient produces a large increase in
a document’s propensity to be classified as relevant (irrelevant). Coefficients for different features are made
comparable by an appropriate normalization: we multiply each feature’s coefficient by the standard devia-
tion of the feature’s values in the training data, producing what is referred to as a ‘standardized coefficient’
in the linear regression literature. For the abstract bigram runs, the following figure shows the ranks of
the most relevant and the reverse rank of the most irrelevant features. RELEVANT FEATURES includes
any feature whose standardized coefficient was among the top 5 most positive standardized coefficients for
any transform/classifier combination, while IRRELEVANT FEATURES includes any feature whose stan-
dardized coefficient was among the top 5 most negative standardized coefficients for any transform/classifier
combination. Transforms are organized in the vertical columns, while classifiers are distinguished by color
and marker style. For relevant (irrelevant) features, markers are positioned according to their rank (reverse
rank) among the most positive (negative) features for a given classifier and transform combination.
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To further compare the importance that different classifier/transform combinations gave to different
features, we performed principal component analysis on a matrix composed of the hyperplane coefficients
of all such combinations. The following figure shows each transform-classifier hyperplane in terms of its
loading on the first two principal components (PCs). This projection separates classifiers that use feature
covariance information (LDA, SVM, and Logistic Regression) and those that don’t (Naive Bayes, dLDA,
VTT). It also groups configurations according to feature transforms, with configurations that included
IDF-like transforms clustering separately from those that used no transforms or a simple L2-normalization.
In general, SVM and Logistic Regression produce very similar feature loadings, likely due to the fact that
they optimize similar cost functions during training.
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1.3 Abstract Performance: NER and Metadata Features
The following figures plot the relative changes in F1 and MCC performance when including vs. not-including
metadata and NER-derived features on abstract bigram runs with feature transforms. Significant changes
(p<0.05, two-tailed test) are indicated by asterisks. For metadata, changes in performance are measured
while still including features from the other 4 metadata fields.
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2 Sentence performance
The following table lists classification performance according to F1, MCC, iAUC, and Accuracy measures
for different classifiers on unigram and bigram sentence runs. It includes the VTTcv classifier (VTT with a
cross-validated threshold), which is not discussed in the main article.
Classifier Type F1 MCC iAUC Accuracy
Log Reg Bigram .734 .630 .823 .848
Log Reg Unigram .734 .629 .818 .847
Naive Bayes Unigram .736 .617 .791 .835
Naive Bayes Bigram .734 .619 .796 .839
SVM Unigram .735 .630 .819 .847
SVM Bigram .736 .633 .824 .848
VTTcv Bigram .733 .608 .797 .822
VTTcv Unigram .729 .608 .789 .831
dLDA Bigram .710 .600 .794 .836
dLDA Unigram .732 .613 .790 .834
LDA Bigram .752 .642 .826 .848
LDA Unigram .750 .636 .819 .843
VTTcv Bigram .733 .608 .797 .822
VTTcv Unigram .729 .608 .789 .831
VTT Bigram .736 .617 .797 .836
VTT Unigram .733 .606 .789 .822
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2.1 Sentence performance: Feature transforms and dimensionality reduction
The following charts show the F1 and MCC performance performance on bigram runs when feature trans-
forms and dimensionality reductions are applied. Significant improvements (p<0.05, one-tailed test) com-
pared to the same classifier applied to non-transformed data are indicated by stars.
- IDF+Norm IDF Norm
TFIDF+
Norm TFIDF
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
0.76
0.77
0.78
0.79
0.80
0.81
0.82
0.83
iA
U
C
Log Reg
SVM
dLDA
LDA
VTT
- IDF+Norm IDF Norm
TFIDF+
Norm TFIDF
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
0.69
0.70
0.71
0.72
0.73
0.74
0.75
0.76
F1
Log Reg
SVM
dLDA
LDA
VTT
- IDF+Norm IDF Norm
TFIDF+
Norm TFIDF
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
-
10
0
20
0
40
0
60
0
80
0
10
00
0.58
0.59
0.60
0.61
0.62
0.63
0.64
0.65
M
C
C
Log Reg
SVM
dLDA
LDA
VTT
2 Sentence performance 8
2.2 Sentence Performance: Most relevant and irrelevant features
We analyzed which features were most relevant and irrelevant for identifying evidence sentences using the
same methodology as for abstracts (described in section 1.2). In the following figure, RELEVANT FEA-
TURES includes any feature whose standardized coefficient was among the top 5 most positive standard-
ized coefficients for any transform/classifier combination, while IRRELEVANT FEATURES includes any
whose standardized coefficient was among the top 5 most negative standardized coefficients for any trans-
form/classifier combination. Transforms are organized in the vertical columns, while classifiers are distin-
guished by color and marker style. For relevant (irrelevant) features, markers are positioned according to
their rank (reverse rank) among the most positive (negative) features for a given classifier and transform
combination.
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As in section 1.2, we perform principal component analysis of separating hyperplanes produced by differ-
ent transforms and classifiers trained on the sentence corpus. Hyperplanes are generally grouped by classifier
in this projection, with those corresponding to ‘naive’ classifiers that do not use feature covariances (VTT,
dLDA, Naive Bayes) clustering separately from those that do (LDA, SVM, Logistic Regression).
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2.3 Sentence Performance: Impact of NER Features
The following figures plot the relative changes in F1 and MCC performance when including vs. not-including
NER-derived features on non-transformed sentence bigram runs. Significant changes (p<0.05, two-tailed test)
indicated by asterisks.
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